Finite element analysis of nonisothermal polymer processing operations

A finite element formulation for the analysis of polymer processing is presented and its use in some typical situation including entry flow, transient Couette flow, and the Graetz (forced convection) problem is illustrated. The element formulations are constructed on the premise that momentum convection can be neglected (polymer melt flows typically have very low Reynolds' numbers), but that convective heat transfer may be significant (high Peclet numbers). Nonisothermal effects are considered important in polymer processing, due in part to the significant heating which may occur due to viscous dissipation, and also to the very strong influence of temperature on fluid viscosity. The flow is treated as Newtonian with the flow field being coupled to the heat transfer equation only through the viscous heat generation

Chemorheology of reactive systems: Finite element analysis

The equations which govern the nonisothermal flow of reactive fluids are outlined, and the means by which finite element analysis is used to solve these equations for the sort of arbitrary boundary conditions encountered in industrial practice are described. The performance of the computer code is illustrated by several trial problems, selected more for their value in providing insight to polymer processing flows than as practical production problems. Although a good deal remains to be learned as to the performance and proper use of this numerical technique, it is undeniably useful in providing better understanding of today's complicated polymer processing problems

Numerical analysis of projectile impact in woven texile structures

Computer codes were developed for simulating the dynamic fracture and viscoelastic constitutive response due to stress wave interaction and reflections caused by ballistic impact on woven textiles. The method, which was developed for use in the design and analysis of protection devices for personnel armor, has potential for use in studies of rotor blade burst containment at high velocity. Alterations in coding required for burst containment problems are discussed

Finite element modeling of nonisothermal polymer flows

A finite element formulation designed to simulate polymer melt flows in which both conductive and convective heat transfer are important is described, and the numerical model is illustrated by means of computer experiments using extruder drag flow and entry flow as trial problems. Fluid incompressibility is enforced by a penalty treatment of the element pressures, and the thermal convective transport is modeled by conventional Galerkin and optimal upwind treatments

Anomalous giant piezoresistance in AlAs 2D electrons with anti-dot lattices

An AlAs two-dimensional electron system patterned with an anti-dot lattice exhibits a giant piezoresistance (GPR) effect, with a sign opposite to the piezoresistance observed in the unpatterned region. We trace the origin of this anomalous GPR to the non-uniform strain in the anti-dot lattice and the exclusion of electrons occupying the two conduction band valleys from different regions of the sample. This is analogous to the well-known giant magnetoresistance (GMR) effect, with valley playing the role of spin and strain the role of magnetic field.Comment: 4 figures, submitted for publicatio

A review of composite structures subjected to dynamic loading

The following review of composite impact work summarises key research interests and provides a brief overview for the development of theoretical, experimental and numerical methods for low, high, and hyper velocity impact. Particular attention is given to experimental apparatus and techniques used for the different impact velocity regimes, and the implementation of failure criteria in finite element (FE) modelling methods which predict material behaviour. Areas are then identified for which limited research has been currently undertaken and suggestions are made for possible future research topics

Evaluating Acute Changes in Joint Range-of-motion using Self-myofascial Release, Postural Alignment Exercises, and Static Stretches

International Journal of Exercise Science 6(4) : 310-319, 2013. This study was designed to compare the acute effect of self-myofascial release (SMR), postural alignment exercises, and static stretching on joint range-of-motion. Our sample included 27 participants (n = 14 males and n = 13 females) who had below average joint range-of-motion (specifically a sit-and-reach score of 13.5 inches [34.3 cm] or less). All were university students 18–27 years randomly assigned to complete two 30–40-minute data collection sessions with each testing session consisting of three sit-and-reach measurements (which involved lumbar spinal flexion, hip flexion, knee extension, and ankle dorsiflexion) interspersed with two treatments. Each treatment included foam-rolling, postural alignment exercises, or static stretching. Participants were assigned to complete session 1 and session 2 on two separate days, 24 hours to 48 hours apart. The data were analyzed so carryover effects could be estimated and showed that no single acute treatment significantly increased posterior mean sit-and-reach scores. However, significant gains (95% posterior probability limits) were realized with both postural alignment exercises and static stretching when used in combination with foam-rolling. For example, the posterior means equaled 1.71 inches (4.34 cm) when postural alignment exercises were followed by foam-rolling; 1.76 inches (4.47 cm) when foam-rolling was followed by static stretching; 1.49 inches (3.78 cm) when static stretching was followed by foam-rolling; and 1.18 inches (2.99 cm) when foam-rolling was followed by postural alignment exercises. Our results demonstrate that an acute treatment of foam-rolling significantly increased joint range-of-motion in participants with below average joint range-of-motion when combined with either postural alignment exercises or static stretching

FANCD2 re-expression is associated with glioma grade and chemical inhibition of the Fanconi Anaemia pathway sensitises gliomas to chemotherapeutic agents.

Brain tumours kill more children and adults under 40 than any other cancer. Around half of primary brain tumours are glioblastoma multiforme (GBMs) where treatment remains a significant challenge. GBM survival rates have improved little over the last 40 years, thus highlighting an unmet need for the identification/development of novel therapeutic targets and agents to improve GBM treatment. Using archived and fresh glioma tissue, we show that in contrast to normal brain or benign schwannomas GBMs exhibit re-expression of FANCD2, a key protein of the Fanconi Anaemia (FA) DNA repair pathway, and possess an active FA pathway. Importantly, FANCD2 expression levels are strongly associated with tumour grade, revealing a potential exploitable therapeutic window to allow inhibition of the FA pathway in tumour cells, whilst sparing normal brain tissue. Using several small molecule inhibitors of the FA pathway in combination with isogenic FA-proficient/deficient glioma cell lines as well as primary GBM cultures, we demonstrate that inhibition of the FA pathway sensitises gliomas to the chemotherapeutic agents Temozolomide and Carmustine. Our findings therefore provide a strong rationale for the development of novel and potent inhibitors of the FA pathway to improve the treatment of GBMs, which may ultimately impact on patient outcome

Cancer History and Systemic Anti-Cancer Therapy Independently Predict COVID-19 Mortality: A UK Tertiary Hospital Experience

Background: The COVID-19 pandemic remains a pressing concern to patients with cancer as countries enter the second peak of the pandemic and beyond. It remains unclear whether cancer and its treatment contribute an independent risk for mortality in COVID-19. Methods: We included patients at a London tertiary hospital with laboratory confirmed SARS-CoV-2 infection. All patients with a history of solid cancer were included. Age- and sex-matched patients without cancer were randomly selected. Patients with hematological malignancies were excluded. Results: We identified 94 patients with cancer, matched to 226 patients without cancer. After adjusting for age, ethnicity, and co-morbidities, patients with cancer had increased mortality following COVID-19 (HR 1.57, 95% CI:1.04–2.4, p = 0.03). Increasing age (HR 1.49 every 10 years, 95% CI:1.25–1.8, p < 0.001), South Asian ethnicity (HR 2.92, 95% CI:1.73–4.9, p < 0.001), and cerebrovascular disease (HR 1.93, 95% CI:1.18–3.2, p = 0.008) also predicted mortality. Within the cancer cohort, systemic anti-cancer therapy (SACT) within 60 days of COVID-19 diagnosis was an independent risk factor for mortality (HR 2.30, 95% CI: 1.16–4.6, p = 0.02). Conclusions: Along with known risk factors, cancer and SACT confer an independent risk for mortality following COVID-19. Further studies are needed to understand the socioeconomic influences and pathophysiology of these associations

Study protocol for a pragmatic randomised controlled trial of comparing enhanced acceptance and commitment therapy plus (+) added to usual aftercare versus usual aftercare only, in patients living with or beyond cancer: SUrvivors' Rehabilitation Evaluation after CANcer (SURECAN) trial.

BACKGROUND: Two million people in the UK are living with or beyond cancer and a third of them report poor quality of life (QoL) due to problems such as fatigue, fear of cancer recurrence, and concerns about returning to work. We aimed to develop and evaluate an intervention based on acceptance and commitment therapy (ACT), suited to address the concerns of cancer survivors and in improving their QoL. We also recognise the importance of exercise and vocational activity on QoL and therefore will integrate options for physical activity and return to work/vocational support, thus ACT Plus (+). METHODS: We will conduct a multi-centre, pragmatic, theory driven, randomised controlled trial. We will assess whether ACT+ including usual aftercare (intervention) is more effective and cost-effective than usual aftercare alone (control). The primary outcome is QoL of participants living with or beyond cancer measured using the Functional Assessment of Cancer Therapy: General scale (FACT-G) at 52 weeks. We will recruit 344 participants identified from secondary care sites who have completed hospital-based treatment for cancer with curative intent, with low QoL (determined by the FACT-G) and randomise with an allocation ratio of 1:1 to the intervention or control. The intervention (ACT+) will be delivered by NHS Talking Therapies, specialist services, and cancer charities. The intervention consists of up to eight sessions at weekly or fortnightly intervals using different modalities of delivery to suit individual needs, i.e. face-to-face sessions, over the phone or skype. DISCUSSION: To date, there have been no robust trials reporting both clinical and cost-effectiveness of an ACT based intervention for people with low QoL after curative cancer treatment in the UK. We will provide high quality evidence of the effectiveness and cost-effectiveness of adding ACT+ to usual aftercare provided by the NHS. If shown to be effective and cost-effective then commissioners, providers and cancer charities will know how to improve QoL in cancer survivors and their families. TRIAL REGISTRATION: ISRCTN: ISRCTN67900293 . Registered on 09 December 2019. All items from the World Health Organization Trial Registration Data Set for this protocol can be found in Additional file 2 Table S1